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Syncope
Therapeutic Approaches
David G. Benditt, MD, John T. Nguyen, MD, MPH
Minneapolis, Minnesota
Syncope is a common clinical problem characterized by transient, spontaneously self-terminating loss of con-
sciousness with complete and prompt recovery; the cause is insufficiency of cerebral oxygen/nutrient supply
most often due to a transient fall of systemic arterial pressure to levels below those tolerated by cerebrovascular
autoregulation. Careful and thorough evaluation of the cause of syncope is warranted in all patients. Determin-
ing that certain individuals are at “low mortality risk” is inadequate; syncope, although often benign from a mor-
tality perspective, tends to recur, is associated with risk of physical injury, diminishes quality-of-life, and might
lead to restriction from employment or avocation. However, the diagnostic evaluation and treatment of syncope
is challenging for many reasons. First, syncope is only 1 of many causes of transient loss of consciousness. Sec-
ond, the patient’s symptoms are fleeting, and the patient is generally fully recovered when seen in the clinic;
only infrequently are there helpful physical findings. Third, spontaneous events are often unwitnessed by med-
ical professionals; consequently, the medical history of symptom events is usually a “second-hand” or
“third-hand” story. Finally, there is often an excessive sense of diagnostic “urgency” that tends to result in a
rush to undertake multiple poorly considered “diagnostic” testing procedures; a deliberate approach based
on initial risk stratification is more likely to reap the dual rewards of a correct diagnosis and initiation of
effective treatment in a cost-effective manner. (J Am Coll Cardiol 2009;53:1741–51) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.065c
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ehe term “syncope” is derived from the Greek word “to cut
hort” or “interrupt”; its use as a descriptor of loss of
onsciousness has been traced back more than 600 years by
ditors of the Oxford English Dictionary. In this context,
e can suppose that the link between the old Greek and
urrent medical usage is the apparently temporary “inter-
uption” of life’s normal activities. However, in modern
sage, “syncope” denotes a particular type of “interruption”
n which: 1) loss of consciousness is temporary; 2) recovery
s spontaneous, prompt, and complete; and 3) the cause is
nsufficiency of cerebral nutrient supply (1). A transient fall
f systemic arterial pressure to levels below cerebrovas-
ular autoregulation requirements is most often to blame.
ther mechanisms, such as abrupt hypoxemic events
e.g., aircraft decompression), are rare.
In practical terms, patients who present with transient
oss of consciousness (TLOC) describe their symptoms with
ords such as “collapse,” “fall,” or “black-out.” In these
ases, “syncope” is only 1 possibility; a broad range of
otential causes for real or presumed TLOC must be
rom the Cardiac Arrhythmia Center, Cardiovascular Division, Department of
edicine, University of Minnesota Medical School, Minneapolis, Minnesota. Dr.
enditt is a consultant to and has equity in Medtronic, Inc., St. Jude Medical,
ardionet, Inc., and Transoma, Inc., manufacturers of diagnostic instruments and
mplantable devices used to evaluate and treat certain syncope patients.r
Manuscript received October 2, 2008; revised manuscript received December 1,
008, accepted December 15, 2008.onsidered. Thus, epilepsy, concussions, metabolic distur-
ances, intoxications, and “syncope mimics” (e.g., psycho-
enic pseudo-syncope, cataplexy) are also contenders; each
iffers from syncope with respect to both pathophysiology
nd treatment.
This review provides an overview for cardiologists of
urrent thought regarding treatment to prevent syncope
ecurrences. However, therapy cannot be examined in iso-
ation; therefore, consideration is also given to a strategy for
he TLOC/syncope evaluation.
iagnostic Approach
horough evaluation of the cause of syncope is warranted in
ll patients. This is important, because syncope, although
erhaps benign from a mortality perspective in most cases,
s rarely a solitary event; recurrences, physical injury, dimin-
shed quality-of-life, and possible lifestyle limitations are
eal concerns (2,3). Consequently, the goal must be to
etermine the cause of syncope with sufficient confidence to
rovide a reliable assessment of prognosis, recurrence risk,
nd treatment options (4).
Among the first questions to be addressed is whether to
onduct the TLOC/syncope evaluation in-hospital or as an
utpatient. Typical current practice patterns tend toward
xcessive in-hospital management. For instance, 1 recent
eport evaluated the frequency with which emergency de-
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Syncope Therapy May 12, 2009:1741–51partment (ED) physicians elected
hospital stay for evaluation of pre-
sumed syncope (5). Despite careful
tutoring regarding European Soci-
ety of Cardiology recommenda-
tions, there was a 25% inappropri-
ate admission rate. Thus, many
ED physicians remain concerned
regarding the appropriateness of
deferring syncope evaluations.
Potentially, greater use of “syn-
cope management units” (SMUs),
“rapid access blackout clinics” (6),
or “TLOC/syncope clinics” might
reduce inappropriate hospital ad-
missions (7,8). For example, in
the SEEDS (Syncope Evaluation
in the Emergency Department
Study) trial patients were ran-
domized to “standard care” or
SMU after initial ED assessment
(an ED-based SMU was used
to manage intermediate-risk pa-
tients for up to 6 h) (8). The
requency of presumptive diagnoses significantly increased
rom 10% in “standard care” patients to 67% with SMU
valuation, whereas both hospital admission frequency (98%
o 43%) and total patient-hospital days (140 to 64 days)
ere less for SMU-managed patients. Furthermore, the
MU approach was more cost-efficient and equally as safe as
he conventional strategy. Similarly, in the multicenter
GSYS-2 (Evaluation of Guidelines in Syncope Study 2)
rial comparing “usual care” to guideline-based “standard-
zed” care in the ED, the standardized group had a lower
ospital stay rate (39% vs. 47%, p 0.001), shorter hospital
tays (approximately 1 day less), fewer diagnostic tests
2.6 vs. 3.4, p  0.001), and an approximately 20% lower
verall cost (7). For EDs without an SMU, an observation
nit similar to that used for “chest pain” assessment might
rove useful.
Apart from more widespread application of SMUs, de-
elopment of effective criteria for determining which pa-
ients require in-hospital evaluation would also reduce
nnecessary admissions. However, despite many proposals
see Table 1 for selected examples) (1,8–13), none are
erfect. For instance, the STePS (Short-Term Prognosis of
yncope) study suggested that an abnormal electrocardio-
ram (ECG), trauma, absence of warning, and male sex
ere markers of short-term (10 days) adverse outcomes
nd therefore warranted hospital stay (9). However, an
ccompanying editorial argued that the STePS study’s
ositive predictive value for separating high- from low-risk
atients was too small to be useful (10). Similarly, attempts
o validate other suggested stratification techniques have led
o variable outcomes. For instance, the ROSE (Risk strat-
Abbreviations
and Acronyms
ECG  electrocardiogram
ED  emergency
department
EPS  electrophysiology
study
ICD  implantable
cardioverter-defibrillator
ILR  implantable
(insertable) loop recorder
NMS  neurally mediated
syncope
PCM  physical counter
maneuvers
RCT  randomized
controlled trial
TLOC  transient loss of
consciousness
SHD  structural heart
disease
SMU  syncope
management unitfication Of Syncope in the Emergency department) study E14) found that clinical judgment was just as accurate as
pplication of the San Francisco Rule (11) for reducing
nneeded hospital admissions.
Our recommendations (Table 2) regarding the need for
ospital stay of patients with presumed syncope are derived
rom the reports in Table 1. In general, hospital admission
s prudent if the suspected underlying problem is associated
ith high risk of early mortality or injury, the proposed
reatment requires in-hospital care, or the affected individ-
al is unable to care for himself or herself.
yncope Classification and Diagnostic Tools
n accurate diagnosis is the essential foundation for effec-
ive treatment of syncope patients (Table 3). However,
espite a well-organized and thorough approach to estab-
ishing a syncope diagnosis (Fig. 1), often it is not possible
o assign a single cause. Multiple comorbidities are com-
on. Thus, individuals with heart disease might faint due to
ransient tachyarrhythmias, high-grade atrioventricular
lock, or overmedication. The physician should not too
uickly accept an observed abnormality to be causal in a
iven individual.
The most valuable tools for establishing the basis of
yncope are a careful medical history aided by eyewitness
eports (1,15,16) and physical findings addressing the pres-
nce of structural heart disease (SHD). It has been reported
hat SHD independently predicts a cardiac cause of syncope
ith 95% sensitivity and 45% specificity (17). Likewise, the
bsence of SHD excluded cardiac syncope in 97% of
atients. Table 4 provides a summary of key findings that
uggest a cardiac origin for syncope.
The 12-lead ECG and echocardiogram are essential
lements of the initial syncope evaluation. Although it is
are that either provides a definitive diagnosis, they might
acilitate choice of subsequent tests. For instance, ECG
ndings summarized in Table 5 or echocardiographic find-
ngs of unsuspected left ventricular dysfunction, dynamic
entricular outflow obstruction, or atrial myxoma/thrombus
ight provide valuable clues.
Extended-duration continuous ECG monitoring with
ither mobile cardiac outpatient telemetry (18) or an im-
lantable loop recorder (ILR) (19–22) has proved valuable
or determining the cause(s) of syncope when events occur
nfrequently. For example, the RAST (Randomized Assess-
ent of Syncope Trial) demonstrated that a primary ILR
iagnostic strategy was twice as effective as a “conventional”
ork-up composed of 2 to 4 weeks of an external ECG loop
ecorder, provocative tilt-table testing, and electrophysi-
logic study (EPS) (19). The EaSyAS (Eastbourne Syncope
ssessment Study) came to a similar conclusion (20). Both
howed substantial ILR cost/diagnosis benefit.
Other tests, including tilt-table testing, EPS, and cardiac
emodynamic evaluation, should be chosen only when the
nitial evaluation supports their use (Fig. 1). Indications for
PS in syncope patients and findings that might help to
Summary of Risk Stratification Assessment for Syncope
Table 1 Summary of Risk Stratification Assessment for Syncope
ESC (1) SEEDS (8) SFRS (11) OESIL (12) EGSYS (13)
Hospital admission recommended to
establish diagnosis
Suspected or known significant heart
disease
ECG abnormalities suggestive of
arrhythmic syncope
Syncope during exercise
Syncope causing severe injury
Family history of sudden death
Hospital admission recommended to
initiate treatment
Cardiac arrhythmias
Syncope due to cardiac ischemia
Syncope secondary to structural cardiac
or cardiopulmonary diseases
Cardioinhibitory neurally mediated
syncope when a pacemaker
implantation is planned
Occasionally might need to be admitted
Patients without heart disease but
sudden onset of palpitations shortly
before syncope
Syncope in supine position
Frequent recurrent episodes
Patients with minimal or mild heart
disease when there is a high
suspicion for cardiac syncope
High risk
Chest pain compatible with acute coronary syndrome
Signs of severe CHF
Moderate to severe valvular heart disease
History of ventricular arrhythmia
ECG/cardiac monitor signs of ischemia
Prolonged QTc (500 ms)
Trifascicular block or pauses between 2 and 3 s
Third-degree atrioventricular block
Persistent sinus bradycardia between 40 and 60
beats/min
Atrial fibrillation or nonsustained ventricular
tachycardia without symptoms
Pacemaker or defibrillator with dysfunction
Intermediate risk
Age 50 yrs
Previous history of CAD, MI, CHF, CMP without active
signs or symptoms on cardiac medications
Bundle-branch block or Q-wave without acute changes
on ECG
Family history of premature unexplained sudden death
(age 50 yrs)
Symptoms not consistent with reflex-mediated or
vasovagal cause
Cardiac devices without evidence of dysfunction
Physician judgment that cardiac cause for syncope
is possible
Low risk
Age 50 yrs
No prior cardiovascular disease
Normal cardiovascular examination
Symptoms consistent with reflex-mediated or
vasovagal syncope
Normal ECG findings
High risk (any of the following):
Abnormal ECG (nonsinus rhythm
or new abnormality)
Shortness of breath
Systolic hypotension (90 mm Hg)
Hematocrit 30%
CHF
Variable
Age 65 yrs
History of CVD
Syncope without
prodromes
Abnormal ECG
12-month all-cause
mortality by score
Score 0  0%
Score 1  0.8%
Score 2  19.6%
Score 3  34.7%
Score 4  57.1%
Score
1
1
1
1
Variable
Palpitations preceding syncope
Heart disease and/or abnormal
ECG
Syncope during effort
Syncope while supine
Precipitating and/or
predisposing factors*
Autonomic prodromes†
3 score cardiac syncope
(95% sensitivity,
67% specificity)
Score
4
3
3
2
1
1
*Warm, crowded place/prolonged orthostasis/fear, pain. †Nausea/vomiting.
CAD coronary artery disease; CHF congestive heart failure; CMP cardiomyopathy; ECG electrocardiogram; EGSYS Evaluation of Guidelines in Syncope Study; ESC European Society of Cardiology; MImyocardial infarction; OESIL Osservatorio Epidemiologico
sulla Sincope nel Lazio; QTc  corrected QT interval; SEEDS  Syncope Evaluation in the Emergency Department Study; SFRS  San Francisco Rule Study.
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Syncope Therapy May 12, 2009:1741–51efine a basis for syncope are summarized in Tables 6 and 7.
eurological tests (e.g., electroencephalography and head
omputed tomography or magnetic resonance imaging) are
lmost never of value, absent concern regarding potential
ntracranial injury (e.g., subdural hematoma) that might
ave been sustained due to a fall.
reatment of Specific Types of Syncope
urrently, treatment of syncope patients relies primarily on
linical experience and observational reports. The principal
xceptions are vasovagal syncope and to a lesser degree
rthostatic hypotension.
eurally mediated reflex syncopal syndromes. Patient
ducation is the foundation of treatment of most neurally
ediated syncope (NMS) syndromes. Patients must be
nformed that, although reflex faints are almost never
ife-threatening (1,23), they tend to recur (often in clusters),
nd injury can result if preventive measures are not taken
eriously. Furthermore, patients might benefit by some
nderstanding of basic pathophysiology and the importance
Risk” Assessment Recommendations Duringnitial Evaluation of Patients With Presumed Syncope
Table 2 “Risk” Assessment Recommendations DuringInitial Evaluation of Patients With Presumed Syncope
General features favoring in-hospital evaluation
Suspected underlying problem is associated with high risk of early mortality
and/or injury
Proposed treatment requires in-hospital care
Affected individual is unable to care for himself or herself
Specific findings supporting in-hospital versus outpatient evaluation
1. Patients with “high risk” warranting hospital stay
Syncope with symptoms suggestive of acute myocardial ischemia or acute
aortic dissection or signs of congestive heart failure, acute pulmonary
embolism, or suspicion of other concerning SHD (e.g., valvular aortic
stenosis, hypertrophic cardiomyopathy)
Syncope during exercise or syncope causing motor vehicle accidents or
severe injury
Family history of premature sudden death
Concerning ECG abnormalities (e.g., pre-excitation, high-grade atrioventricular
block, prolonged pauses [typically 3 to 5 s], ventricular tachycardia)
Evidence of a channelopathy (i.e., long/short QT syndrome, Brugada
syndrome)
2. Patients with “intermediate risk” (admission if physician’s “judgment” favors
cardiac cause for syncope)
First syncope at age 50 yrs
SHD absent active consequences of disease
Suspected implanted cardiac device (pacemaker, defibrillator, prosthetic
valve) malfunction
3. Patients with “low risk” who might be referred for outpatient evaluation
(preferably to a “Syncope Clinic”*)
Absence of evident SHD and a normal ECG
History of recurrent syncope over many years
Suspicion of “syncope mimic” (e.g., psychogenic pseudo-syncope)
The “low risk” group of patients is the largest subgroup of “syncope” patients, and averting an
nnecessary hospital stay can have important cost-savings. It comprises primarily vasovagal,
situational,” and most orthostatic (those without severe primary autonomic disease) faints.
yncope is of relatively “benign” nature in terms of mortality, but “falls risk” is a concern. Thus,
irtually all vasovagal fainters and many orthostatic syncope patients (excluding perhaps elderly
ersons with excessive injury risk) can be discharged after careful discussion of the problem,
nstruction regarding basic preventative maneuvers, and follow-up arrangement.
ECG  electrocardiogram; SHD  structural heart disease.f recognizing and responding to warning symptoms; suchnderstanding not only reduces injury risk but also might
ltimately enhance treatment compliance. In addition, it is
mportant to identify and treat psychological and/or psychi-
tric factors that might contribute to exacerbating symptom
usceptibility. In this regard, a high prevalence of minor
sychiatric disorders has been reported in patients with
asovagal syncope (24,25).
Recurrent vasovagal fainters should learn techniques for
borting imminent attacks and reducing susceptibility to future
ttacks (e.g., physical maneuvers, liberalized salt intake, hydra-
ion). They should also be taught the value and possible risks of
ncreased salt intake. In situational faints, it might be possible
o ameliorate or avoid triggers. For instance, one might target
ough suppression and smoking cessation in “cough syncope”
nd sitting while voiding in “micturition syncope.” In some
ases (e.g., syncope associated with fear of air flight), desensi-
ization techniques might help.
Carotid sinus syndrome is a special form of NMS (1,26)
hat tends to occur in older individuals and predisposes
lassification of the Principal Causesf Syncope in Descending Order of Frequency
Table 3 Classification of the Principal Causesof Syncope in Descending Order of Frequency
Neurally mediated reflex syncope
Vasovagal (“common”) faint
Carotid sinus syndrome
Situational faints (e.g., cough, defecation, excessive heat, micturition,
pain, prolonged upright posture, sneeze, swallow, venipuncture,
volume depletion)
Post-exercise variant
Other (e.g., brass instrument playing, weightlifting, post-prandial)
Glossopharyngeal and trigeminal neuralgia
Orthostatic syncope
Secondary autonomic failure syndromes (e.g., diabetic neuropathy, amyloid
neuropathy, drugs and alcohol)
Volume depletion (e.g., hemorrhage, diarrhea, Addison’s disease)
Primary autonomic failure syndromes (e.g., pure autonomic failure, multiple
system atrophy, Parkinson’s disease with autonomic failure)
Postural intolerance syndromes (e.g., postural orthostatic tachycardia
syndrome) in which syncope occurs occasionally, probably of reflex origin
Cardiac arrhythmias as primary cause
Sinus node dysfunction (including bradycardia/tachycardia syndrome) and
atrioventricular conduction system disease
Paroxysmal supraventricular and ventricular tachycardias (including
“channelopathies”: e.g., long QT syndrome, Brugada syndrome, short QT,
arrhythmogenic right ventricular dysplasia)
Implanted device (pacemaker, implantable cardioverter-defibrillator)
malfunction, drug-induced proarrhythmias
Structural cardiac or cardiopulmonary disease
Acute myocardial infarction/ischemia
Cardiac valvular disease
Obstructive cardiomyopathy
Acute aortic dissection
Pulmonary embolus/pulmonary hypertension
Atrial myxoma
Pericardial disease/tamponade
Cerebrovascular
Migraine (most often neurally-mediated reflex in origin)Vascular steal syndromes
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May 12, 2009:1741–51 Syncope Therapyhem to falls and injury (26). In such cases, although
voidance of tight collars, neckties, and abrupt neck move-
ents is prudent advice, early initiation of cardiac pacing is
sually recommended (1,27,28).
As alluded to earlier, physical counter-pressure maneuvers
PCM) are increasingly advocated to abort imminent NMS or
rthostatic faints in patients who are aware of warning symp-
oms. Thus, squatting, arm-tensing, leg-crossing, and leg-
rossing with lower body muscle tensing have proved useful for
verting an abrupt vasovagal reaction (29,30) (Fig. 2). In the
C-Trial (Physical Counterpressure Manoeuvres Trial), PCM
educed total burden and recurrence rate of syncopal events
31). In brief, “usual” therapy plus PCM was compared with
usual” therapy alone in patients with recognizable warning
linical Findings Suggesting a Cardiac Basisor Syncope: Primary Arrhythmia and/ortru tural Origin
Table 4
Clinical Findings Suggesting a Cardiac Basis
for Syncope: Primary Arrhythmia and/or
Structural Origin
Physical examination and/or echocardiographic evidence of severe structural
heart disease
Syncope during exertion or while in supine position
Palpitations at the time of syncope
History of heart failure
Acute or prior acute myocardial infarction
Evidence of left ventricular dysfunction
Figure 1 Initial Approach to the Evaluation of Suspected Synco
Diagnostic pathway for evaluation of suspected syncope (see the Syncope Classifi
fied from that proposed in the European Society of Cardiology syncope guidelines.
cardiogram; Echo  echocardiogram; EP  electrophysiologic; ILR  implantable lO
eymptoms. The syncope burden during follow-up was lower in
CM-trained patients versus control subjects; overall, 32% of
CM-trained and 51% of conventional arm patients experi-
nced syncope recurrence (p 0.005). Recurrence-free survival
as better with PCM (39% relative risk reduction). Conse-
uently, PCM should be part of the treatment strategy in
atients with warning symptoms.
Strategies for reducing syncope recurrences in the long-
erm comprise: 1) physical techniques to improve ortho-
tatic tolerance; 2) pharmacologic interventions to prevent
chocardiogram Findings Suggestingrrhythm c C use of Syncope
Table 5 Echocardiogram Findings SuggestingArrhythmic Cause of Syncope
Third-degree atrioventricular block
Intermittent atrioventricular block (i.e., high-grade, Mobitz II, Mobitz I
in elderly patients)
Sustained severe sinus bradycardia (40 beats/min) while awake, sinoatrial
block, or sinus pause 3 s duration
Pre-excited QRS complexes (e.g., Wolff-Parkinson-White syndrome)
Prolonged/short QT interval
Brugada pattern
Negative T waves in right precordial leads, epsilon waves, and ventricular late
potentials suggestive of arrhythmogenic right ventricular dysplasia
ST-segment or T-wave changes suggesting acute myocardial infarction/ischemia
and Diagnostic Tools section for details). The approach advocated here is modi-
 ambulatory electrocardiogram; CSM  carotid sinus massage; ECG  electro-
corder; Rx  treatment; SHD  structural heart disease.ften these findings are not definitive evidence, and additional studies are needed (e.g., continuousAbnormal electrocardiogram findings (Table 5)pe
cation
AECG
oop relectrocardiogram monitoring, electrophysiologic study).
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Syncope Therapy May 12, 2009:1741–51epletion of intravascular volume and/or enhance arterial
nd venous tone; and 3) cardiac pacing to avert bradycardia.
HYSICAL TECHNIQUES. The goal of “tilt-training” (more
ccurately termed “standing-training”) is to enhance neuro-
ascular response to orthostatic stress (32) (Fig. 3). Initially
he “tilt-training” concept used repeated in-hospital expo-
ure to postural stress by tilt-table tests until syncope was no
onger inducible. However, this approach is impractical.
urrently, the method entails home “standing-training” for
rogressively longer periods of time over 10 to 12 weeks. At
he beginning, the recommended standing duration is 3 to
min twice daily; standing duration is then gradually
engthened every 3 to 4 days to as much as 30 to 40 min
wice daily.
Nonrandomized studies suggest that tilt-training reduces
MS susceptibility if undertaken consistently (33–35).
owever, compliance is a limitation, and randomized ob-
ervations have been less encouraging (36). Further studies
re needed.
yncope Due to Cardiac Arrhythmias:ndi ations for Electrophysiologic Study
Table 6 Syncope Due to Cardiac Arrhythmias:Indications for Electrophysiologic Study
Class I
Abnormal electrocardiogram suggesting conduction system cause
Syncope during exertion or in supine position or with important structural
heart disease
Syncope with palpitations or angina-like chest pain
Family history of sudden death
Class II
Define/ablate an arrhythmia that has already been identified
In patients with high-risk occupations
Class III
Absence of risk factors above, unless suspected paroxysmal supraventricular
tachycardia
PS Findings in the Syncope Evaluation
Table 7 EPS Findings in the Syncope Evaluation
Diagnostic (usually no additional tests are required)
Sinus bradycardia and a very prolonged SNRT
HV interval 100 ms
Second- or third-degree His-Purkinje block during atrial pacing
High-degree His-Purkinje block is provoked by intravenous administration of
ajmaline, procainamide, or disopyramide
Induction of sustained monomorphic VT (usually 150 beats/min)
Induction of sustained SVT with hypotension or rate 180 beats/min
Diagnosis is less well-established in case of
HV interval of 70 ms but 100 ms
Induction of polymorphic VT or ventricular fibrillation in patients with Brugada
syndrome or arrhythmogenic right ventricular dysplasia
Reproducible induction of nonsustained VT or SVT with rates 180 beats/min
Nondiagnostic
Induction of polymorphic VT or ventricular fibrillation in patients with ischemic
or dilated cardiomyopathy
normal electrophysiology study (EPS) cannot completely exclude an arrhythmic cause of syncope;
hen an arrhythmia is likely, further evaluations (e.g., implantable loop recorder placement) are
ecommended. If not consistent with the clinical context, abnormal EPS might not be diagnostic of
he cause of syncope (i.e., a detected “abnormality” is not necessarily a “diagnosis”).p
HV  His bundle ventricular; SNRT  sinus node recovery time; SVT  supraventricular
achycardia; VT  ventricular tachycardia.HARMACOTHERAPY. A number of drugs, including “over-
he-counter” remedies of uncertain composition and safety,
re commonly prescribed for prevention of NMS. However,
here are few randomized clinical trials, and consequently no
gent, excepting perhaps midodrine, can be said to have
Figure 2 Physical Maneuvers to Counter an
Imminent Vasovagal or Orthostatic Faint
Schematics illustrating physical counter-maneuvers designed to delay an immi-
nent vasovagal or orthostatic faint. Each of these maneuvers might boost
blood pressure sufficiently to delay symptoms. The objective is to “buy time”
during which the affected individual can seek a safe haven. (A) The subject is
depicted using leg-crossing with lower body muscle tensing (left) or squatting
(right) to enhance blood pressure. (B) Arm-tensing is illustrated. Figure illustra-
tions by Rob Flewell.roven effectiveness.
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May 12, 2009:1741–51 Syncope TherapyVolume expansion has been the foundation of medical
herapy for both vasovagal faints and orthostatic syncope
discussed in later text). Conventional approaches to volume
xpansion entail increased dietary salt and electrolyte-rich
port drinks (although it is wise to avoid many high-caloric
sport” drinks) (37). The primary safety concern is induction
f hypertension. This is uncommon in younger patients but
s a greater concern in older patients.
Among prescription drugs for volume expansion, fludro-
Figure 3 Tilt-Training (Standing-Training)
Schematic illustrating the “tilt-training” technique for home use. Patients are
instructed to stand and place only the upper back against a wall (with ankles
approximately 15 cm away from the wall) without moving. The sessions are
initially performed in a quiet and comfortable environment (possibly under
supervision of a family member). The patient stands still with upper back posi-
tioned lightly against a wall or a corner. A carpeted floor is preferred, and the
nearby environment should be devoid of sharp-edged objects or other hazards
should the patient fall. Initially we recommend 3 to 5 min of standing twice
daily. Then, depending on symptom status, the duration can be slowly
increased each week. The target is 20 to 30 min twice daily without symp-
toms. Thereafter, 20 min sessions 3 to 4 times/week are recommended indef-
initely. Figure illustration by Rob Flewell.ortisone (a synthetic mineralocorticoid) is the most widely Hsed, especially in younger patients (38). Side effects in-
lude hypertension and hypokalemia. However, clinical
vidence of fludrocortisone efficacy is weak. For instance, in
dolescents, Scott et al. (39) demonstrated no benefit over
tenolol in preventing recurrence of syncope in a random-
zed trial. Similarly, Salim and Di Sessa (40) found fludro-
ortisone to be less effective than placebo in preventing
yncope or pre-syncope in children. A larger randomized
ontrolled trial (RCT) with fludrocortisone in vasovagal
yncope is ongoing (POST II [Second Prevention of
yncope Trial]) (41).
Among other drug classes proposed for prevention of
asovagal faints, the beta-adrenoceptor antagonists (beta-
lockers) were thought to reduce susceptibility by diminish-
ng the impact of the adrenergic surge that commonly
recedes and might be part of the trigger (15,42–44).
owever, supportive evidence is derived largely from obser-
ational reports and a single small RCT (45). More recently
relatively large RCT (POST [Prevention of Syncope
rial]) showed no clear beta-blocker benefit in terms of
yncope recurrence prevention (46). In the POST trial, 208
atients with 2 syncopal events each were randomized to
reatment with metoprolol or placebo. During a 1-year
ollow-up syncope recurrence was similar in both groups.
owever, somewhat surprisingly, older metoprolol-treated
atients (age 42 years) seemed to show some benefit,
lbeit not statistically significant.
Vasoconstrictors and venoconstrictors have also been of
nterest in this setting. Etilephrine, a modest alpha- and
eta-agonist, was studied in the VASIS (Vasovagal Inter-
ational Study) but did not prove effective (47). Currently,
idodrine is the principal vasoconstrictor for this indica-
ion. Midodrine is a pro-drug, metabolized in the liver to
he active agent, desglymidodrine, which acts to constrict
oth arterial and venous beds, thus increasing peripheral
lood pressure, improving venous return, and diminishing
enous pooling. Midodrine has been most extensively stud-
ed in patients with orthostatic hypotension (48) but has
lso been shown to be effective in vasovagal syncope (49,50).
idodrine only infrequently causes hypertension, but it
ight precipitate urinary retention or urgency in older men
nd occasionally induces scalp “tingling” presumably due to
iloerector muscle contraction. Methylphenidate has been
roposed as an alternative for midodrine-intolerant patients
51); however, its value has not been established. Further-
ore, unlike midodrine, methylphenidate crosses the blood
rain barrier and can cause multiple adverse effects (e.g.,
gitation, movement disturbances, irritability).
Finally, several other drugs have been advocated but at
est remain of uncertain effectiveness. Foremost among
hese are selective serotonin reuptake inhibitors (52). It has
een postulated that an abnormal hypersensitive serotonin
esponse in the central nervous system contributes to trig-
ering NMS; selective serotonin reuptake inhibitor pre-
reatment is thought to blunt this abnormal response.owever, although 1 RCT showed reduced syncope recur-
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Syncope Therapy May 12, 2009:1741–51ence in 30 patients taking active medication compared with
lacebo (53), a subsequent study showed no benefit (54).
ther agents—disopyramide, pure anticholinergics (e.g.,
copolamine), and theophylline—have also been proposed,
ut the reported experience for any of these is small,
ncontrolled, and currently unconvincing.
ARDIAC PACING. As noted earlier, cardiac pacing has long
een considered an essential part of the treatment of carotid
inus syndrome (26,27,55,56). However, the role of pacing
n patients with “refractory” vasovagal syncope is less certain.
he proposed mode of benefit is thought to be prevention
f severe bradycardia (cardio-inhibitory syncope). However,
lthough 3 unblinded RCTs (the VPS [North American
asovagal Pacemaker Study] [57], the VASIS trial [47],
nd the SYDIT [Syncope Diagnosis and Treatment] study
58]) showed efficacy for pacing, 2 subsequent trials in
hich pacemakers were present in both treatment arms
VPS II [Second Vasovagal Pacemaker Study] [59] and
YNPACE [Vasovagal Syncope and Pacing Trial] [60]) did
ot show benefit. A larger ongoing multicenter study
ISSUE-3 [International Study on Syncope of Uncertain
tiology 3] [61]) is addressing some of the shortcomings
f prior studies, but results will not be available for 2 to 3
ears. Until then, cardiac pacing is recommended only
or older vasovagal fainters with documented symptomatic
systolic pauses during spontaneous faints (e.g., docu-
ented by ILR).
rthostatic syncope and related autonomic distur-
ances. Orthostatic syncope results from an excessive fall
f systemic pressure (hypotension) triggered by postural
hange (e.g., supine or sitting to upright posture). In
uantitative terms, clinically significant orthostatic hypoten-
ion is defined as a reduction of systolic blood pressure of
20 mm Hg and/or a diastolic fall of 10 mm Hg within
min of standing, regardless of whether symptoms occur.
Orthostatic hypotension might be caused by: 1) impaired
apacity of sympathetic nerves to increase vascular resistance
ue to primary nervous system disease or secondary to other
iseases or drugs (or toxins) that adversely affect the auto-
omic nervous system; 2) relative volume depletion;
) downward pooling of venous blood and a consequent
eduction in stroke volume and cardiac output; or 4) impaired
ardiac diastolic relaxation, especially of the aged or hypertro-
hied heart. Orthostatic syncope might be due specifically to:
) primary autonomic neurological disturbance (e.g., pure
utonomic failure, multiple system atrophy, Parkinson’s
isease); 2) drugs (e.g., vasodilators, diuretics); or 3) ac-
uired disease (e.g., diabetes, alcohol, and so on) (62,63).
revention is often difficult. When caused by a primary
utonomic disease process, progress can often be made
lowly if the patient is persistent with therapy, but complete
eturn to “normal” is not a reasonable expectation. The best
ase is orthostatic syncope caused by nonessential drugs that
an be eliminated.Treatment of orthostatic syncope parallels the strategy
iscussed earlier for vasovagal and situational faints, with
ertain differences: 1) the duration of treatment is likely to
e longer; 2) affected individuals are typically older and
railer, making PCM more difficult to employ; and 3) patients
re more prone to supine hypertension.
Treatment should focus initially on education about
actors that aggravate or provoke postural hypotension
Table 8). Thereafter, patients should be advised regarding
aintenance of hydration (volume expanders are encour-
ged with careful follow-up to avoid excessive hyperten-
ion) as discussed in the reflex syncope section, PCM
Fig. 2), and “tilt-training” (Fig. 3). Furthermore, patients
ith autonomic failure should be advised to sleep with the
ead of the bed somewhat elevated (approximately 20 to 25
m). Finally, vasoconstrictors such as midodrine (see the
receding text) might be introduced. However, fluctuating
lood pressures and supine hypertension are often encoun-
ered. In such cases it is essential to try to tailor timing of
herapy to support the arterial pressure during daytime and
o prevent hypertension at night (while also minimizing risk
f falling when affected individuals get out of bed in the
iddle of the night).
A special case is the patient with severe pure autonomic
ailure. In these individuals, bolus water intake, especially
efore rising from bed in the morning, might result in a
aluable increase in blood pressure (64). This technique
ight also be worth trying in other patients with postural
ypotension in whom symptoms are often most trouble-
ome in the morning (after prolonged absence of oral intake
nd increased supine renal filtration).
Other agents advocated for treatment of orthostatic
ypotension in specialized circumstances include erythro-
oietin (65,66), clonidine (67), octreotide (68), and desmo-
ressin (69). However, evidence supporting each of these is
arginal.
ardiac arrhythmias as primary cause of syncope. Deter-
ining that a specific cardiac arrhythmia is responsible for
yncope remains a diagnostic challenge. The initial evalua-
ion might provide clues, but selected diagnostic tests are
sually required. Long-term ECG monitoring is often
arranted. In this regard, among wearable ECG event
ecorders, mobile cardiac outpatient telemetry devices have
ommon Factors Thatncrease Risk of Orthostatic Syncope
Table 8 Common Factors ThatIncrease Risk of Orthostatic Syncope
Sudden head-up postural change (especially upon waking in the morning)
Standing still for a prolonged period of time
Certain prescription drugs (e.g., diuretics, vasodilators)
Severe exertion with dehydration
Diminished “thirst drive” in elderly persons
Avoidance of fluid intake in older men (to minimize prostate symptoms)
Excess alcohol or caffeine
Straining during micturition or defecation
High environmental temperature (including hot baths, showers, and saunas)Large meals (especially with refined carbohydrates)
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May 12, 2009:1741–51 Syncope Therapyeen shown to be superior to conventional event recorders
n syncope patients (18). Additionally, the ISSUE study
llustrated, in terms of implantable monitors, the diagnostic
alue of ILRs in syncope patients, in particular for those
ith underlying evidence of conduction system disease (70)
r SHD (71). In the former case, bradyarrhythmias tended
o predominate, whereas in the latter, the detected arrhyth-
ias were more heterogeneous. In some instances but not
ften, EPS is needed (Table 6). Apart from its diagnostic
alue, invasive EPS also offers the potential to cure certain
rrhythmias by transvenous catheter ablation, a technique
ow available in most EPS laboratories.
In the case of cardiac arrhythmias being the primary cause
f syncope, treatment decisions are directed at the specific
ocumented arrhythmia (1). Cardiac pacemakers are highly
ffective for bradyarrhythmias, whether due to underlying
onduction system disease or, as is often the case in older
atients, the effects of essential drug therapy (e.g., beta-
lockers, anti-arrhythmic drugs). Tachyarrhythmic origins
f syncope often lead to consideration of EPS mapping and
blation. For example, ablation is usually recommended as
nitial therapy for many supraventricular tachycardias and
entricular tachycardias of right or left ventricular outflow
ract origin or due to bundle-branch re-entry. The effec-
iveness of ablation in paroxysmal atrial fibrillation causing
yncope is less certain. In some cases, His bundle ablation
ith permanent pacing might be a valuable back-up option.
Absent the possibility of a curative ablation procedure, it
s often necessary to use combinations of antiarrhythmic
rugs along with implanted devices (pacemakers or implant-
ble cardioverter-defibrillators [ICDs]). Thus, in patients
ith certain channelopathies (e.g., long QT syndrome,
rugada syndrome, short QT syndrome), the life-
hreatening risk is often too great to rely on medications
lone (e.g., beta-blockade in some long QT syndrome
atients), and an ICD is recommended. However, ICDs
lone might not prevent syncope, due to the time taken to
iagnose the arrhythmia and initiate treatment. For in-
tance, in an examination of data gleaned from SCD-HeFT
Sudden Cardiac Death in Heart Failure Trial), rates of
yncope did not differ between the 3 treatment arms (ICD,
miodarone, placebo) (72).
tructural cardiovascular and cardiopulmonary disease.
ost often, syncope associated with SHD is secondary to
ither neurally mediated reflex mechanisms (e.g., acute
yocardial ischemia) or primary arrhythmias, both of which
ave been discussed in the preceding text. In certain cases,
owever, hemodynamic studies reveal abnormalities of suf-
cient severity to indicate that SHD is directly responsible
e.g., severe aortic stenosis or mitral stenosis or obstructive
CM). In such instances, symptom prevention is best
chieved by ameliorating the primary structural disturbance
f possible. Thus, severe valvulopathies require surgery,
hereas obstructive HCM can often be managed with drugs
nd possibly cardiac pacing (73). In other circumstances,
owever, currently available interventions cannot provide tdequate protection; pulmonary hypertension might be the
ost important example.
erebrovascular syncope. Migraines due to vascular
pasm might be the most important cause of syncope in this
ection; however, this mechanism must be rare, because it
ould require simultaneous multivessel involvement. More
ikely, the origin of faints in migraineurs might be related to
n element of associated autonomic dysfunction (74) and in
articular vasovagal events triggered by pain and nausea. In
ny case, the medical management includes use of beta-
lockers and cranial/basilar artery vasoconstrictors such as
umatriptan (75). Subclavian steal syndrome is another
ondition in this category that might cause faints, but these
re very rare; its treatment requires either surgical or
atheter-based intervention (76).
Structural cerebrovascular disease might cause strokes and
ransient ischemic attacks but is almost never the cause of
yncope. One very infrequent exception might be vertebro-
asilar transient ischemic attacks, but these are usually
ccompanied by other posterior circulation symptoms such
s vertigo. The treatment of transient ischemic attacks lies
utside the boundaries of this review.
onclusions
he evaluation and treatment of syncope is challenging.
irst, “syncope” is only one of many causes of TLOC.
econd, symptoms are fleeting, and the patient is usually
symptomatic when seen in the clinic. Third, events are
ften unwitnessed; but even when witnessed, the stress of
he moment might undermine reliability of the account.
inally, there is often an excessive sense of diagnostic
urgency”; this results in a rush to undertake multiple poorly
onsidered “diagnostic” testing procedures. A deliberate
pproach based on initial risk stratification is more likely to
eap the reward of a correct diagnosis.
Despite the difficulties, a thorough evaluation of the
ause of syncope is warranted in all patients—not just in
hose deemed to be at high mortality risk. Conversely,
he mere presence of an abnormal finding does not
onstitute a “diagnosis.” The physician must carefully
onsider whether detected abnormalities are compatible
ith the clinical circumstances. The goal in every case
hould be to determine the cause with sufficient confi-
ence to provide a reliable assessment of prognosis and
reatment options.
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